OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Clinical Oncology is 85. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Clinical development and potential of photothermal and photodynamic therapies for cancer	1567
Broadening horizons: the role of ferroptosis in cancer	1155
Targeting apoptosis in cancer therapy	1123
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	779
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors	657
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	616
Immunotherapies for hepatocellular carcinoma	609
Liquid biopsy enters the clinic — implementation issues and future challenges	580
Exploring the NK cell platform for cancer immunotherapy	569
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities	559
Unlocking the potential of antibody–drug conjugates for cancer therapy	484
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	462
Clinical and therapeutic relevance of cancer-associated fibroblasts	397
TGFβ biology in cancer progression and immunotherapy	395
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	389
Roles and mechanisms of alternative splicing in cancer — implications for care	374
The emerging roles of circRNAs in cancer and oncology	368
Immune-checkpoint inhibitors: long-term implications of toxicity	341
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	340
Advancing therapy for osteosarcoma	309
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	302
Harnessing cytokines and chemokines for cancer therapy	297
T cell-engaging therapies — BiTEs and beyond	282
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic	280
The SWI/SNF complex in cancer — biology, biomarkers and therapy	279

Rising incidence of early-onset colorectal cancer — a call to action	259
The adenosine pathway in immuno-oncology	258
Exploiting the folate receptor α in oncology	251
Lineage plasticity in cancer: a shared pathway of therapeutic resistance	247
Clinical relevance of tumour-associated macrophages	242
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	239
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	229
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives	210
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	210
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper	206
Nasopharyngeal carcinoma: an evolving paradigm	195
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	194
Understanding and overcoming resistance to PARP inhibitors in cancer therapy	193
Moving towards personalized treatments of immune-related adverse events	184
Therapeutic targeting of the hypoxic tumour microenvironment	176
Clinical implications of T cell exhaustion for cancer immunotherapy	170
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	169
Personalized early detection and prevention of breast cancer: ENVISION consensus statement	166
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	165
Targeting drugs to tumours using cell membrane-coated nanoparticles	164
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	160
Tumour budding in solid cancers	159
Artificial intelligence in radiation oncology	156
MET-dependent solid tumours — molecular diagnosis and targeted therapy	156
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	154
The implications of IDH mutations for cancer development and therapy	150
CAR T cell therapies for patients with multiple myeloma	150
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	149
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	143
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	143
Senescence and cancer — role and therapeutic opportunities	136
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	133
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	133
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	132
Towards precision medicine for AML	130
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	129
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	127
Immunogenicity of CAR T cells in cancer therapy	123
ROS1-dependent cancers — biology, diagnostics and therapeutics	122
The current state of the art and future trends in RAS-targeted cancer therapies	118
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire	118
Fundamentals and developments in fluorescence-guided cancer surgery	117
The emerging role of photoacoustic imaging in clinical oncology	115
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	114
Long-term outcomes following CAR T cell therapy: what we know so far	110
Precision oncology in metastatic colorectal cancer — from biology to medicine	108
The nuclear export protein XPO1 — from biology to targeted therapy	108
Integrating evolutionary dynamics into cancer therapy	107
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	107
The blood–tumour barrier in cancer biology and therapy	104

Tumour burden and efficacy of immune-checkpoint inhibitors	102
Advancing therapy for neuroblastoma	95
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	94
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	94
Protein degraders enter the clinic — a new approach to cancer therapy	93
Circulating tumour DNA — looking beyond the blood	92
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice	91
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	89
Radiotheranostics in oncology: current challenges and emerging opportunities	89
Novel approaches to target the microenvironment of bone metastasis	88